202 related articles for article (PubMed ID: 32085516)
1. Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status.
Currò M; Ferlazzo N; Giunta ML; Montalto AS; Russo T; Arena S; Impellizzeri P; Caccamo D; Romeo C; Ientile R
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085516
[TBL] [Abstract][Full Text] [Related]
2. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
3. MYCN and HIF-1 directly regulate
Hains AE; Uppal S; Cao JZ; Salwen HR; Applebaum MA; Cohn SL; Godley LA
Epigenetics; 2022 Dec; 17(13):2056-2074. PubMed ID: 35942521
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.
Qing G; Skuli N; Mayes PA; Pawel B; Martinez D; Maris JM; Simon MC
Cancer Res; 2010 Dec; 70(24):10351-61. PubMed ID: 20961996
[TBL] [Abstract][Full Text] [Related]
5. Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation.
Tee AEL; Marshall GM; Liu PY; Xu N; Haber M; Norris MD; Iismaa SE; Liu T
J Biol Chem; 2010 Feb; 285(6):3561-3567. PubMed ID: 20007697
[TBL] [Abstract][Full Text] [Related]
6. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
7. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
8. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
9. CO
Currò M; Arena S; Montalto AS; Perrone P; Di Fabrizio D; Bertuccio MP; Mazzeo C; Caccamo D; Ientile R; Romeo C; Impellizzeri P
Pediatr Surg Int; 2022 Mar; 38(3):457-464. PubMed ID: 35083505
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
11. Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
Zonca S; Pinton G; Wang Z; Soluri MF; Tavian D; Griffin M; Sblattero D; Moro L
Cell Death Dis; 2017 Feb; 8(2):e2592. PubMed ID: 28151477
[TBL] [Abstract][Full Text] [Related]
12. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
Liu HJ; Li GL; Lei PC
Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
[No Abstract] [Full Text] [Related]
13. Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization.
Gundemir S; Colak G; Feola J; Blouin R; Johnson GV
Biochim Biophys Acta; 2013 Jan; 1833(1):1-10. PubMed ID: 23085038
[TBL] [Abstract][Full Text] [Related]
14.
De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482
[TBL] [Abstract][Full Text] [Related]
15. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
17. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
18. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.
Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K
Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729
[TBL] [Abstract][Full Text] [Related]
19. Activation of transglutaminase 2 by nerve growth factor in differentiating neuroblastoma cells: A role in cell survival and neurite outgrowth.
Algarni AS; Hargreaves AJ; Dickenson JM
Eur J Pharmacol; 2018 Feb; 820():113-129. PubMed ID: 29242118
[TBL] [Abstract][Full Text] [Related]
20. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
